Ph.D., Capricor’s chief executive officer. “This study further demonstrates the potential for an exosome-based therapeutic approach to exhibit better cellular uptake and promote higher exon ...
Ph.D., Capricor’s chief executive officer. “In addition, we continue to advance our proprietary StealthX™ platform technology as part of our long-term strategy to leverage exosomes as vehicles for ...